Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor–positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial

Schmid, P., Zaiss, M., Harper-Wynne, C. et al. (29 more authors) (2019) Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor–positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial. JAMA Oncology. ISSN 2374-2445

Abstract

Metadata

Authors/Creators:
  • Schmid, P.
  • Zaiss, M.
  • Harper-Wynne, C.
  • Ferreira, M.
  • Dubey, S.
  • Chan, S.
  • Makris, A.
  • Nemsadze, G.
  • Brunt, A.
  • Kuemmel, S.
  • Ruiz, I.
  • Perello, A.
  • Kendall, A.
  • Brown, J.
  • Kristeleit, H.
  • Conibear, J.
  • Saura, C.
  • Grenier, J.
  • Mahr, K.
  • Schenker, M.
  • Sohn, J.
  • Lee, K.S.
  • Shepherd, C.
  • Oelmann, E.
  • Sarker, S.-J.
  • Prendergast, A.
  • Marosics, P.
  • Moosa, A.
  • Lawrence, C.
  • Coetzee, C.
  • Mousa, K.
  • Cortes, J.
Copyright, Publisher and Additional Information: © 2019 2019 Schmid P et al. This is an open access article distributed under the terms of the CC-BY-NC-ND License (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Dates:
  • Accepted: 17 April 2019
  • Published (online): 29 August 2019
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 03 May 2019 08:46
Last Modified: 30 Aug 2019 13:58
Status: Published online
Publisher: American Medical Association
Refereed: Yes
Identification Number: https://doi.org/10.1001/jamaoncol.2019.2526

Share / Export

Statistics